한글목차

경구용 항당뇨병제 세계 시장 규모는 2024년에 180억 2,000만 달러로 평가되었고, 2030년에는 259억 4,000만 달러에 이를 것으로 예측되며, 예측 기간 중의 CAGR은 6.22%를 나타낼 전망입니다.

이 시장은 당뇨병 세계 유병률 증가와 의약품 연구의 지속적인 발전으로 현저한 성장을 이루고 있습니다. 당뇨병은 인구 고령화, 좌식 라이프 스타일, 건강에 해로운 식생활 등의 요인으로 인해 발생하며 환자 수가 엄청나게 증가하고 있습니다. 그 결과 다양하고 효과적인 경구 치료제에 대한 요구가 급증하고 있습니다. 이 시장에는 설포닐우레아제, 비구아나이드제, DPP-4 억제제, SGLT2 억제제, GLP-1 수용체작용제 등 다양한 약물 클래스가 있으며, 각각 다른 메커니즘으로 혈당 조절을 하고 있습니다. 경쟁은 여전히 치열하고, 대기업 제약 기업부터 신흥 기업까지 기술 혁신과 시장 점유율 확대를 목표로 삼고 있습니다. 당뇨병 관리 솔루션의 개선에 대한 수요 증가는 이 역동적이고 필수적인 건강 관리 분야 전반에 대한 연구와 투자를 계속 자극하고 있습니다.

시장 성장 촉진요인

세계 당뇨병 이환율 증가

주요 시장 과제

높은 건강 관리 비용

주요 시장 동향

맞춤형 의료 접근법

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 목소리

제5장 세계 경구용 항당뇨병제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 약제별(비구아나이드 약, α-글루코시다아제 억제제, 도파민 D2 수용체 작동제, 나트륨-글루코오스 공수송체-2(SGLT-2) 억제제, 디펩티딜펩티다아제-4(DPP-4) 억제제, 설포닐우레아제, 메글리티니드)
  • 최종 사용자(병원, 재택 케어, 전문센터, 기타)
  • 기업별(2024년)
  • 지역별
• 시장 맵

제6장 북미의 경구용 항당뇨병제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 경구용 항당뇨병제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 경구용 항당뇨병제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 경구용 항당뇨병제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 경구용 항당뇨병제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 합병과 인수

제13장 PESTEL 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체약의 위협

제15장 경쟁 구도

• KONINKLIJKE PHILIPS NV
• Sanofi SA
• Eli Lilly and Company
• AstraZeneca
• Astellas Pharma Inc.
• Johnson & Johnson(Janssen Pharmaceuticals)
• Boehringer Ingelheim
• Merck And Co.
• Bristol Myers Squibb Company
• Novartis AG

제16장 전략적 제안

제17장 기업 소개와 면책사항

영문목차

The Global Oral Anti-Diabetic Drugs Market was valued at USD 18.02 Billion in 2024 and is projected to reach USD 25.94 Billion by 2030, growing at a CAGR of 6.22% during the forecast period. This market has witnessed notable growth due to the rising global prevalence of diabetes and continuous advancements in pharmaceutical research. Diabetes, driven by factors such as aging populations, sedentary lifestyles, and unhealthy diets, has created a vast and growing patient pool. As a result, the need for diverse and effective oral treatment options has surged. The market encompasses a wide array of drug classes, including Sulfonylureas, Biguanides, DPP-4 Inhibitors, SGLT2 Inhibitors, and GLP-1 Receptor Agonists, each addressing different mechanisms of glucose control. Competition remains robust, with established pharmaceutical giants and emerging companies striving for innovation and greater market share. The growing demand for improved diabetes management solutions continues to stimulate research and investment across this dynamic and essential healthcare sector.

Key Market Drivers

Increasing Global Diabetes Prevalence

The rapidly growing incidence of diabetes globally is a key force driving the Oral Anti-Diabetic Drugs (OAD) market. According to the International Diabetes Federation (IDF), approximately 589 million adults aged 20-79 are living with diabetes in 2024, representing 11.1% of the global adult population. This number is expected to rise to 643 million by 2030 and 853 million by 2050. A 2024 Lancet study further highlights that around 828 million adults were affected by diabetes as of 2022. This sharp increase is attributed to lifestyle changes including physical inactivity, poor nutrition, and population aging. These factors significantly elevate the risk of type 2 diabetes, prompting a surge in demand for effective oral therapies. As the diabetic population grows, so does the need for accessible and reliable medications, underscoring the crucial role of oral anti-diabetic drugs in modern disease management.

Key Market Challenges

High Healthcare Costs

One of the major challenges in the Oral Anti-Diabetic Drugs market is the high cost associated with comprehensive diabetes care. This includes not only medications but also glucose monitoring devices, routine consultations, and hospitalization in case of complications. For many patients-especially in low- and middle-income countries-the affordability and accessibility of these treatments remain significant concerns. The price of oral anti-diabetic drugs forms a substantial part of diabetes-related expenditures, and for those lacking adequate insurance or financial support, these expenses can be burdensome. This economic pressure can result in reduced adherence to treatment regimens, ultimately impacting health outcomes and exacerbating disease progression. Managing these cost-related challenges is essential to ensure broader access to effective diabetes therapies.

Key Market Trends

Personalized Medicine Approaches

Personalized medicine is emerging as a transformative trend in the Oral Anti-Diabetic Drugs market. Recognizing that diabetes is a complex and heterogeneous condition, healthcare providers are moving towards customized treatment strategies tailored to each patient's genetic makeup, comorbidities, and personal preferences. Advances in genetic testing and biomarker analysis now allow for more accurate drug selection and dosing, enhancing treatment efficacy while reducing the risk of adverse effects. The shift away from a "one-size-fits-all" model is improving patient outcomes and safety. Personalized therapies are particularly valuable in complex cases where standard treatments may not deliver optimal results, making this trend a key driver of innovation and patient satisfaction in the market.

Key Market Players

• KONINKLIJKE PHILIPS N.V.
• Sanofi S.A.
• Eli Lilly and Company
• AstraZeneca
• Astellas Pharma Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Boehringer Ingelheim
• Merck And Co.
• Bristol Myers Squibb Company
• Novartis AG

Report Scope:

In this report, the Global Oral Anti-Diabetic Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Oral Anti-Diabetic Drugs Market, By Drugs:

• Biguanides
• Alpha-glucosidase inhibitors
• Dopamine -D2 Receptor Agonist
• Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
• Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
• Sulfonylureas
• Meglitinides

Oral Anti-Diabetic Drugs Market, By End Users:

• Hospitals
• Homecare
• Speciality Centers
• Others

Oral Anti-Diabetic Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Oral Anti-Diabetic Drugs Market.

Available Customizations:

Global Oral Anti-Diabetic Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Oral Anti-Diabetic Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine -D2 Receptor Agonist, Sodium-glucose Cotransport -2 (SGLT-2) inhibitor, Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides)
  • 5.2.2. End Users (Hospitals, Homecare, Speciality Centres, Others)
  • 5.2.3. By Company (2024)
  • 5.2.4. By Region
• 5.3. Market Map

6. North America Oral Anti-Diabetic Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drugs
  • 6.2.2. By End Users
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Oral Anti-Diabetic Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drugs
      • 6.3.1.2.2. By End Users
  • 6.3.2. Mexico Oral Anti-Diabetic Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drugs
      • 6.3.2.2.2. By End Users
  • 6.3.3. Canada Oral Anti-Diabetic Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drugs
      • 6.3.3.2.2. By End Users

7. Europe Oral Anti-Diabetic Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drugs
  • 7.2.2. By End Users
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drugs
      • 7.3.1.2.2. By End Users
  • 7.3.2. Germany Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drugs
      • 7.3.2.2.2. By End Users
  • 7.3.3. United Kingdom Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drugs
      • 7.3.3.2.2. By End Users
  • 7.3.4. Italy Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drugs
      • 7.3.4.2.2. By End Users
  • 7.3.5. Spain Oral Anti-Diabetic Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drugs
      • 7.3.5.2.2. By End Users

8. Asia-Pacific Oral Anti-Diabetic Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drugs
  • 8.2.2. By End Users
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drugs
      • 8.3.1.2.2. By End Users
  • 8.3.2. India Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drugs
      • 8.3.2.2.2. By End Users
  • 8.3.3. South Korea Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drugs
      • 8.3.3.2.2. By End Users
  • 8.3.4. Japan Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drugs
      • 8.3.4.2.2. By End Users
  • 8.3.5. Australia Oral Anti-Diabetic Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drugs
      • 8.3.5.2.2. By End Users

9. South America Oral Anti-Diabetic Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drugs
  • 9.2.2. By End Users
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Oral Anti-Diabetic Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drugs
      • 9.3.1.2.2. By End Users
  • 9.3.2. Argentina Oral Anti-Diabetic Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drugs
      • 9.3.2.2.2. By End Users
  • 9.3.3. Colombia Oral Anti-Diabetic Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drugs
      • 9.3.3.2.2. By End Users

10. Middle East and Africa Oral Anti-Diabetic Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drugs
  • 10.2.2. By End Users
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Oral Anti-Diabetic Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drugs
      • 10.3.1.2.2. By End Users
  • 10.3.2. Saudi Arabia Oral Anti-Diabetic Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drugs
      • 10.3.2.2.2. By End Users
  • 10.3.3. UAE Oral Anti-Diabetic Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drugs
      • 10.3.3.2.2. By End Users

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Drugs

15. Competitive Landscape

• 15.1. KONINKLIJKE PHILIPS N.V.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (In case of listed companies)
  • 15.1.5. Recent Developments
  • 15.1.6. SWOT Analysis
• 15.2. Sanofi S.A.
• 15.3. Eli Lilly and Company
• 15.4. AstraZeneca
• 15.5. Astellas Pharma Inc.
• 15.6. Johnson & Johnson (Janssen Pharmaceuticals)
• 15.7. Boehringer Ingelheim
• 15.8. Merck And Co.
• 15.9. Bristol Myers Squibb Company
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer